The significance of secukinumab in the treatment of plaque psoriasis

Abstract

Psoriasis is a chronic inflammatory skin disease that affects approximately 1–3% of the general population in Poland. It is estimated that in 70–80% of patients skin lesions are mild and require only topical medications. In severe plaque psoriasis, classic treatments often lead to a loss of efficacy, adverse effects or insufficient treatment effect, therefore it is necessary to search for new therapeutic methods. Multiple studies show that secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has significant efficacy in the treatment of moderate to severe psoriasis, demonstrating a rapid onset of action and sustained response with a good safety profile. The role of secukinumab in the treatment of plaque psoriasis is discussed in this article.

Keywords

• secukinumab
• psoriasis
• biological treatment